Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
Status:
Completed
Trial end date:
2021-05-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the clinical benefit, as measured by overall
survival, of nivolumab with that of. dacarbazine in patients with previously untreated,
unresectable, or metastatic melanoma